<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="185728">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676026</url>
  </required_header>
  <id_info>
    <org_study_id>0505027759</org_study_id>
    <nct_id>NCT00676026</nct_id>
  </id_info>
  <brief_title>Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women</brief_title>
  <official_title>The Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this series of challenge studies is to examine the impact of menstrual cycle
      phase on cortical GABA response to administration of agents with either direct
      (benzodiazepines) or indirect (progesterone, fluoxetine) GABA modulating properties. While
      the impact of these agents on cortical GABA levels in women with premenstrual dysphoric
      disorder (PMDD) is of interest, this study is designed primarily for those women without a
      psychiatric illness.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the impact of GABA-A receptor agonists (benzodiazepines, allopregnanolone) and other GABA-modulating agents (fluoxetine) on cortical GABA levels by menstrual cycle phase as measured using 1H-MRS in healthy controls.</measure>
    <time_frame>Each medication will be administered 2 times during a 1-month menstrual cycle.</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Zolpidem 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zolpidem will be administered twice to each participant; once in the follicular and luteal phases of the menstrual cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoxetine 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluoxetine will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.</description>
    <arm_group_label>Fluoxetine 3</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.</description>
    <arm_group_label>Zolpidem 1</arm_group_label>
    <other_name>Ambien</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.</description>
    <arm_group_label>Progesterone 2</arm_group_label>
    <other_name>Prometrium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ages 18-45 and able to give voluntary written informed consent;

          -  Regular menstrual periods of 24-35 days in length;

          -  Body mass index 18.5 to 30 kg/m2;

          -  No past or present DSM-IV psychiatric or substance dependence diagnosis by structured
             diagnostic interview (SCID-NP); no substance abuse history within the previous 2
             years;

          -  Absence of mood symptoms across the menstrual cycle during one month of prospective
             daily ratings with the Daily Record of Severity of Problems (DRSP); the DRSP is based
             on the DSM-IV research criteria for premenstrual dysphoric disorder (PMDD) and has
             been used in numerous studies to confirm the presence or absence of significant
             premenstrual mood and behavioral difficulties;

          -  Must be willing and able to participate in at least three of the four challenge
             paradigms.

        Exclusion Criteria:

          -  Medical, neurologic or cerebrovascular disorder (CVA, seizure disorder, etc.);

          -  Family history of first degree relative with an Axis I psychiatric or substance
             dependence disorder (excepting alcohol and nicotine) (per subject report);

          -  Current treatment with psychoactive medication;

          -  Diabetes controlled by means other than diet;

          -  Use of steroid contraceptives (any method involving hormones) within the previous 4
             months;

          -  Habitual consumption of more than 7 alcoholic drinks per week or more than 2 drinks
             on any particular occasion; must be willing to abstain from alcohol consumption for
             48 hours prior to each 1H-MRS scan;

          -  Implanted metallic devices.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia N Epperson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine; Yale Program for Women's Reproductive Behavioral Health</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 1, 2016</lastchanged_date>
  <firstreceived_date>April 7, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>menses</keyword>
  <keyword>women</keyword>
  <keyword>healthy controls</keyword>
  <keyword>Healthy females with regular menstrual cycles</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zolpidem</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
